 Study endpoints: primary endpoint is the anti-depression efficacy response rate. Response defined as the PHQ-9 or HAMD-17 questionnaire score decrease 50 compared with baseline level. Secondary endpoints included: 1.recovery rate, recovery defined as the PHQ-9 score less than 8 points. 2. Response duration, defined as the time period from treatment response to regression recurrence PHQ-9 score ascending above baseline level. 3. Quality of life improvement, define as the best quality of life score minus baseline level. 4. Compliance to anti-depression therapy, defined as the medication count at each follow-up time points. 